This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: Communicable diseases, Subject name: Social & Preventive Medicine
[{'content': 'Which of the following drug is not used in MDB under RNTCP \nSelect and explain. \nA. Levofloxacin, B. Cycloserine, C. PAS, D. Ethionamide', 'role': 'user'}, {'content': 'Answer: C \nExplanation: Regimen for MDR-TB This regimen comprises of 6 drugs Kanamycin, Levofloxacin, Ethionamide, Pyrazinamide, Ethambutol and Cycloserine during 6-9 months of the intensive phase and 4 drugs-Levovfloxacin, Ethionamide, Ethambutol and Cycloserine during the 18 months of the continuation phase. RNTCP regimen for MDR-TB : 6 (9) Km Lvx Eto Cs Z E/ 18 Lvx Eto Cs E* (Reserve/substitute drugs : PAS, Mfx, Cm) Special adjustments to the standard regimen for MDR-TB are as follows: In case of intolerance to Kanamycin, then Capreomycin (or PAS if injectable agent not feasible) is the available substitute drug. - In case of intolerance leading to discontinuation of other oral second-line drug, p-aminosalicylic acid (PAS) is the available substitute drug. - Baseline Kanamycin mono-resistance should lead to substitution of Kanamycin with Capreomycin. - Baseline Ofloxacin mono-resistance should lead to substitution of Levofloxacin with the combination of Moxifloxacin and PAS. - Baseline Ofloxacin and Kanamycin resistance (i.e. XDR-TB) should lead to declaration of outcome, referral to DR-TB Centre for pre-treatment evaluation for regimen for XDR-TB. Ref : Park 23rd edition Pgno : 191', 'role': 'assistant'}]